The firm, which specialises in commercialising public and corporate research, has closed its largest fund to date.

Arch Venture Partners, a US-based venture capital firm with a focus on commercialising university research, closed its eleventh fund at $1.85bn yesterday to back biotechnology companies. Fund XI will seek both to create and invest in early-stage companies across areas including infectious disease, mental health, immunology, oncology, neurology, manufacturing, clinical trials, anti-aging medicines, genomic and…

The rest of this content is only accessible to University Venturing: News, Data and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.